Shan H. Siddiqi, M.D. (1), Mary L. Creech, R.N., M.S.W., L.C.S.W. (2), Kevin J. Black, M.D. (1-4)* ORCID 0000-0002-6921-9567
Departments of (1) Psychiatry, (2) Neurology, (3) Radiology, and (4) Anatomy & Neurobiology, Washington University School of Medicine, St. Louis, Missouri, USA
* Address correspondence to Dr. Black at Campus Box 8134, 660 S. Euclid Ave., St. Louis, Missouri, USA or kevin@WUSTL.edu
Copyright © 2015, the authors
This is a preprint of an article whose final published version is now freely available at https://peerj.com/articles/1198/. Preferred citation:
Intravenous levodopa has been used in a multitude of research studies due to its more predictable pharmacokinetics compared to the oral form, which is used frequently as a treatment for Parkinson’s disease (PD). Levodopa is the precursor for dopamine, and intravenous dopamine would strongly affect vascular tone, but peripheral decarboxylase inhibitors are intended to block such effects. Pulse and blood pressure, with orthostatic changes, were recorded before and after intravenous levodopa or placebo—after oral carbidopa—in 13 adults with a chronic tic disorder and 16 tic-free adult control subjects. Levodopa caused no statistically or clinically significant changes in blood pressure or pulse. These data add to previous data that support the safety of i.v. levodopa when given with adequate peripheral inhibition of DOPA decarboxylase.
levodopa, intravenous, carbidopa, randomized controlled trial, blood pressure, heart rate, Tourette syndrome